ATTN: We are committed to keeping our patients informed regarding the recent cybersecurity incident involving McKesson. At this time, we are continuing to monitor the situation closely and are working to obtain the most current information available. We will provide updates as we receive additional information from McKesson and learn more about any potential impact. Thank you for your patience and trust as we navigate this situation together. CLICK HERE for more information.

Virginia Oncology Associates

Virginia Oncology Associates

Clinical Research & Trials

Cancer Center » Clinical Research & Trials » Available Trials » USO 24268
Patient Portal Cancer Resources

Listen to our podcast

RSS Feed

USO 24268

NX-5948-201: A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)

 

Disease Types: Lymphoma & Hematologic

Eligibility Requirements:

• Confirmed diagnosis of relapsed/refractory CLL/SLL
• ECOG ≤2
• Subjects must have prior exposure to a cBTKi, ncBTKi,
and BCL-2i either in separate LOT or in combination
• Subjects must have measurable disease by CT
• Subjects previously treated with a BTK degrader are
excluded
• Subjects with a known or suspected prolymphocytic
leukemia or Richter’s transformation are excluded

For more information on this trial CLICK HERE .

Available at:

Virginia Oncology Associates